Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/94240
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Papademetriou, V. | - |
dc.contributor.author | Tsioufis, C. | - |
dc.contributor.author | Sinhal, A. | - |
dc.contributor.author | Chew, D. | - |
dc.contributor.author | Meredith, I. | - |
dc.contributor.author | Malaiapan, Y. | - |
dc.contributor.author | Worthley, M. | - |
dc.contributor.author | Worthley, S. | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Hypertension, 2014; 64(3):565-572 | - |
dc.identifier.issn | 0194-911X | - |
dc.identifier.issn | 1524-4563 | - |
dc.identifier.uri | http://hdl.handle.net/2440/94240 | - |
dc.description.abstract | Renal denervation has emerged as a novel approach for the treatment of patients with drug-resistant hypertension. To date, only limited data have been published using multielectrode radiofrequency ablation systems. In this article, we present the 12-month data of EnligHTN I, a first-in-human study using a multielectrode ablation catheter. EnligHTN I enrolled 46 patients (average age, 60±10 years; on average 4.7±1.0 medications) with drug-resistant hypertension. Eligible patients were on ≥3 antihypertensive medications and had a systolic blood pressure (BP) ≥160 mm Hg (≥150 mm Hg for diabetics). Bilateral renal artery ablation was performed using a percutaneous femoral approach and standardized techniques. The average baseline office BP was 176/96 mm Hg, average 24-hour ambulatory BP was 150/83 mm Hg, and average home BP was 158/90 mm Hg. The average reductions (mm Hg) at 1, 3, 6, and 12 months were as follows: office: -28/-10, -27/-10, -26/-10, and -27/-11 mm Hg (P<0.001 for all); 24-hour ambulatory: -10/-5, -10/-5, -10/-6 (P<0.001 for all), and -7/-4 for 12 months (P<0.0094). Reductions in home measurements (based on 2-week average) were -9/-4, -8/-5,-10/-7, and -11/-6 mm Hg (P<0.001 at 12 months). At 12 months, there were no signals of worsening renal function and no new serious or life-threatening adverse events. One patient with baseline nonocclusive renal artery stenosis progressed to 75% diameter stenosis, requiring renal artery stenting. The 12-month data continue to demonstrate safety and efficacy of the EnligHTN ablation system in patients with drug-resistant hypertension. Home BP measurements parallel measurements obtained with 24-hour ambulatory monitoring. | - |
dc.description.statementofresponsibility | Vasilios Papademetriou, Costas P. Tsioufis, Ajay Sinhal, Derek P. Chew, Ian T. Meredith, Yuvi Malaiapan, Matthew I. Worthley, Stephen G. Worthley | - |
dc.language.iso | en | - |
dc.publisher | Lippincott Williams and Wilkins | - |
dc.rights | © 2014 American Heart Association, Inc. | - |
dc.source.uri | http://dx.doi.org/10.1161/hypertensionaha.114.03605 | - |
dc.subject | ambulatory blood pressure; home blood pressure; multielectrode; renal denervation; resistant hypertension | - |
dc.title | Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1161/HYPERTENSIONAHA.114.03605 | - |
pubs.publication-status | Published | - |
Appears in Collections: | Aurora harvest 2 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.